Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 18,391 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed Phase 4 Interventional

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

NCT00035256
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, raloxifene HCl, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Maywood, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 15, 2007 · Synced Oct 21, 2026, 4:26 AM EDT
Active, not recruiting Not applicable Interventional

Pain Reduction Using NEurostimulation Study

NCT05311956
View directory record Official record
Conditions
End Stage Kidney Disease, Chronic Pain
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational

Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease

NCT00600951
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting No phase listed Observational

Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study

NCT02841553
View directory record Official record
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Deafness, Diabetes Insipidus, Ataxia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
0 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Phase 1 Interventional

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

NCT00044837
View directory record Official record
Conditions
HIV Infections
Interventions
Medroxyprogesterone acetate, Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Trial of Using SmokeBeat to Monitor and Increase Smoking Abstinence in Pregnant Women

NCT03209557
View directory record Official record
Conditions
Tobacco Use Cessation, Pregnancy Related
Interventions
SmartWatch SmokeBeat Application
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE

NCT05909046
View directory record Official record
Conditions
Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk, Gestational Diabetes, Gestational Diabetes Mellitus in the Puerperium
Interventions
Immediate inpatient postpartum OGTT, Standard of care 4-12 week postpartum OGTT
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

NCT01178827
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, oxybutynin IR, oxybutynin IR placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 21, 2026, 4:26 AM EDT
Not yet recruiting No phase listed Observational

Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness

NCT07356986
View directory record Official record
Conditions
Gestational Diabetes, Postpartum
Interventions
Dexcom Stelo real-time Continuous Glucose Monitor
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Santa Barbara, California • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

In Vitro Maturation (IVM) of Human Oocytes

NCT01843569
View directory record Official record
Conditions
Polycystic Ovarian Syndrome (PCOS), Patients Sensitive to Exogenous Gonadotropins, Ovarian Hyper Stimulation Syndrome (OHSS)
Interventions
In Vitro maturation
Biological
Lead sponsor
Northwell Health
Other
Eligibility
25 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function and Cognition in CKD

NCT03689569
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Resistant starch, Exercise, Starch
Dietary Supplement · Behavioral
Lead sponsor
Springfield College
Other
Eligibility
30 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Overnight Pant Study for Children With Nocturnal Enuresis

NCT05178641
View directory record Official record
Conditions
Nocturnal Enuresis
Interventions
Ninjamas Pyjama Pants, Participant's Overnight Current Standard of Care
Device · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
4 Years to 7 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Choline Dose Ranging in Postmenopausal Women

NCT06924541
View directory record Official record
Conditions
Menopause
Interventions
Choline, Placebo
Dietary Supplement
Lead sponsor
Julie Dumas
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

NCT00234494
View directory record Official record
Conditions
Bladder Cancer
Interventions
Cisplatin, Gemcitabine, Bevacizumab
Drug
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
11
States / cities
Chicago, Illinois • Galesburg, Illinois • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Research Study Exploring How Musculoskeletal Function and the Autonomic Nervous System Relate to Visceral Pain in Women With and Without Dysmenorrhea (Painful Periods).

NCT07209566
View directory record Official record
Conditions
Dysmenorrhea, Dysmenorrhea Primary, Visceral Pain, Menstrual Pain
Interventions
Visceral Pain Stimulus
Diagnostic Test
Lead sponsor
Azusa Pacific University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

NCT02718066
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Interventions
HBI-8000 in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Port Saint Lucie, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography

NCT04397029
View directory record Official record
Conditions
Breast Cancer
Interventions
SureTouch
Device
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Results available

Colonizing Neurogenic Bladders With Benign Flora

NCT00371631
View directory record Official record
Conditions
Spinal Cord Injury, Urinary Tract Infection
Interventions
Insertion of urinary catheters coated with E. coli 83972
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pembrolizumab, Trebananib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

NCT00034372
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
oregovomab
Drug
Lead sponsor
Unither Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
12
States / cities
Newport Beach, California • Stanford, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Oct 21, 2026, 4:26 AM EDT
Active, not recruiting Phase 2 Interventional

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

NCT06106295
View directory record Official record
Conditions
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions
Metyrapone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

TVT-SECUR as an Office-based Procedure

NCT01137539
View directory record Official record
Conditions
Urinary Incontinence, Stress Urinary Incontinence
Interventions
Gynecare TVT-SECUR system
Device
Lead sponsor
Michigan Institution of Women's Health PC
Other
Eligibility
21 Years to 89 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 21, 2026, 4:26 AM EDT